Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

BACKGROUND: Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7t...

Descripción completa

Detalles Bibliográficos
Autores principales: Casarrubios, Marta, Provencio, Mariano, Nadal, Ernest, Insa, Amelia, del Rosario García-Campelo, María, Lázaro-Quintela, Martín, Dómine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Massuti, Bartomeu, Sierra-Rodero, Belén, Martinez-Toledo, Cristina, Fernández-Miranda, Ismael, Serna-Blanco, Roberto, Romero, Atocha, Calvo, Virginia, Cruz-Bermúdez, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528578/
https://www.ncbi.nlm.nih.gov/pubmed/36171009
http://dx.doi.org/10.1136/jitc-2022-005320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528578/
https://www.ncbi.nlm.nih.gov/pubmed/36171009
http://dx.doi.org/10.1136/jitc-2022-005320

Ejemplares similares